Tests NKT5097 pill in adults with advanced solid tumors, including breast cancer
Tests a new pill, NKT5097, for adults with advanced breast cancer or solid tumors.
Key facts
- Who runs it
- NiKang Therapeutics, Inc.
- Where
- Boston, Cleveland, Dallas, Denver, Duarte, Fairfax, Grand Rapids, Houston, Iowa City, La Jolla, Las Vegas, Morgantown, New Haven, Pittsburgh, San Antonio, Sarasota, St Louis, Washington D.C., and West Valley City, United StatesSee the 19 sites
- Trial code
- Registry title
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 361 people, planned
- Started
- 25 Mar 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 5 groups
- Treatments tested
- NKT5097 CDK2/CDK4 dual degrader
- Fulvestrant
- Letrozole
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors, with a focus on breast cancer and tumors with CCNE1 amplification. It tests the safety of the oral drug NKT5097.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced tumor that cannot be removed by surgery, or metastatic solid tumor. Parts 4 and 5: advanced or metastatic HR+/HER2- breast cancer. Measurable or evaluable disease is needed in some parts.
- Earlier treatment
- Parts 1, 2 and 4: the cancer did not respond to existing therapies, or the person cannot tolerate them. Part 5: no earlier selective investigational inhibitors or degraders.
- Biomarker or test result
- Willing to provide tumor tissue. ECOG status of 0 or 1.
Main reasons for not taking part
- Advanced tumor that can still be treated with the aim of removing all of the disease
- Another cancer in the past, with a few listed exceptions
- Known active cancer spread to the brain or its lining
- Heart or blood vessel event such as heart attack or stroke within 6 months
- Significant liver disease (Child Pugh class B or C)
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Able to provide written informed consent
- Advanced unresectable or metastatic solid tumor (Part 1, 2 \& 3 only)
- Advanced unresectable or metastatic HR+/HER2- breast cancer (Part 4 \& 5 only)
- Refractory to or unable to tolerate existing therapies (Part 1, 2 \& 4 only)
- Measurable or evaluable disease (Part 1, 2, \& 4 only)
- Measurable disease (Part 3 \& 5 only)
- Eighteen years of age or older
- ECOG status of 0 or 1
- Adequate organ function
- Patients with female reproductive organs must be surgically sterile, post- menopausal or willing to use effective contraception per protocol
- Patients who are capable of insemination must be willing to use highly effective contraception and to refrain from sperm donation during treatment and for 28 days after the last dose
- Able to swallow oral meds
- Willing to provide tumor tissue
Who cannot take part
- Not recovered from the effects of prior anticancer therapy
- Major surgery within 30 days of administration of first dose
- Should not have received any prior selective investigational inhibitors or degraders (Part 5 only)
- History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage I or Stage II cancers currently in complete remission
- Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months
- Active interstitial lung disease requiring treatment
- History of uveitis, retinopathy, or other clinically significant retinal disease
- Active uncontrolled infectious disease
- Significant liver disease (Child Pugh class B or C)
- Advanced solid tumor that is a candidate for curative treatment
- Known active CNS metastases and/or carcinomatous meningitis
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesContact: Antonio Giordano, MD (principal investigator)Taking people
- Cleveland ClinicCleveland, United StatesContact: Cancer AnswerTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Jennifer KnightTaking people
- Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: Gerald Falchook, MD (principal investigator)Taking people
- City of HopeDuarte, United StatesContact: Jenny SanchezTaking people
- NEXT VirginiaFairfax, United StatesContact: Blake PattersonTaking people
- South Texas Accelerated Research Therapeutics (START) MidwestGrand Rapids, United StatesContact: Ashley SpagnuoloTaking people
- MD Anderson Cancer CenterHouston, United StatesContact: Ileana GutierrezTaking people
- University of IowaIowa City, United StatesContact: Clinical Trial Inquiry LineTaking people
- UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Cristal MartinezTaking people
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesContact: Ann LovelaceTaking people
- West Virginia UniversityMorgantown, United StatesContact: Emily HawkinsTaking people
- Yale Cancer CenterNew Haven, United StatesContact: Priscilla SteveTaking people
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Julie UrbanTaking people
- South Texas Accelerated Research Therapeutics | START San AntonioSan Antonio, United StatesContact: Isabel JimenezTaking people
- SCRI Florida Cancer Specialists - SarasotaSarasota, United StatesContact: Carly TaylorTaking people
- Washington UniversitySt Louis, United StatesContact: Katlyn KraftTaking people
- Georgetown University Medical CenterWashington D.C., United StatesContact: Julie CastleTaking people
- South Texas Accelerated Research Therapeutics (START) Mountain RegionWest Valley City, United StatesContact: HOPE TeamTaking people
About the trial
What the trial wants to find out
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include:
Read full original descriptionShow less
* What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET
The 5 groups in the trial
- Part 1 Dose EscalationTreatment being tested
Escalation of orally administered NKT5097
Treatment: NKT5097 CDK2/CDK4 dual degrader
- Part 2 Food EffectTreatment being tested
Orally administered NKT5097 with and without meal
Treatment: NKT5097 CDK2/CDK4 dual degrader
- Part 3 ExpansionTreatment being tested
Expansion of dose levels based upon safety and PK following Part 1 escalation.
Treatment: NKT5097 CDK2/CDK4 dual degrader
- Part 4 Combination Dose EscalationTreatment being tested
Escalation of orally administered NKT5097 in combination with Endocrine Therapy (ET)
Treatment: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, and Letrozole
- Part 5 Combination ExpansionTreatment being tested
Expansion of dose levels based upon safety and PK following Part 4 escalation
Treatment: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, and Letrozole
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
- Plain-language title
- Tests NKT5097 pill in adults with advanced solid tumors, including breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 November 2026